(Q36501675)

14 August 2017

1 reference

title

Biologic therapies for inflammatory eye disease (English)

1 reference

14 August 2017

Lyndell Lim

1

1 reference

14 August 2017

Eric B Suhler

series ordinal

2

1 reference

14 August 2017

Justine R Smith

series ordinal

3

1 reference

14 August 2017

publication date

1 May 2006

1 reference

Clinical and Experimental Ophthalmology

14 August 2017

published in

1 reference

14 August 2017

volume

34

1 reference

14 August 2017

issue

4

1 reference

14 August 2017

page(s)

365-374

1 reference

Antiinflammatory action of glucocorticoids--new mechanisms for old drugs

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Campath-1H therapy in refractory ocular inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Successful treatment of Wegener's granulomatosis associated scleritis with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

The therapeutic potential of anti-CD20 "what do B-cells do?".

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Treatment of sarcoidosis with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Anti-TNF-alpha therapy for sight threatening uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Infliximab in the treatment of refractory posterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

The benefit/risk profile of TNF-blocking agents: findings of a consensus panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

The German etanercept registry for treatment of juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Etanercept: a review of its use in the management of plaque psoriasis and psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Etanercept therapy in children with treatment-resistant uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Efficacy of Etanercept in Preventing Relapse of Uveitis Controlled by Methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Etanercept plus standard therapy for Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Daclizumab to prevent rejection after cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Intravenous immune globulin therapy for neurologic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Rheumatoid arthritis: non-tumor necrosis factor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Inhibition of IL-6 for the treatment of inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-9071.2006.01225.X

10.1111/J.1442-9071.2006.01225.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference